Characterization of Thrombin Generation Curve Shape in Presence of Platelets from Acute Venous Thromboembolism Patients
Abstract
:1. Introduction
2. Experimental Section
3. Results and Discussion
4. Conclusions
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Lane, D.A.; Philippou, H.; Huntington, J.A. Directing thrombin. Blood 2005, 106, 2605–2612. [Google Scholar] [CrossRef]
- Roberts, H.R.; Monroe, D.M.; Oliver, J.A.; Chang, J.Y.; Hoffman, M. Newer concepts of blood coagulation. Haemophilia 1998, 4, 331–334. [Google Scholar] [CrossRef]
- Hemker, H.C.; Giesen, P.; AlDieri, R.; Regnault, V.; de Smed, E.; Wagenvoord, R.; Lecompte, T.; Béguin, S. The calibrated automated thrombogram (CAT): A universal routine test for hyper—and hypocoagulability. Pathophysiol. Haemost. Thromb. 2002, 32, 249–253. [Google Scholar] [CrossRef]
- Al Dieri, R.; de Laat, B.; Hemker, H.C. Thrombin generation: What have we learned? Blood Rev. 2012, 26, 197–203. [Google Scholar] [CrossRef]
- Besser, M.; Baglin, C.; Luddington, R.; van Hylckama Vlieg, A.; Baglin, T. High rate of unprovoked recurrent venous thrombosis is associated with high thrombin-generating potential in a prospective cohort study. J. Thromb. Haemost. 2008, 6, 1720–1725. [Google Scholar] [CrossRef]
- Lutsey, P.L.; Folsom, A.R.; Heckbert, S.R.; Cushman, M. Peak thrombin generation and subsequent venous thromboembolism: The Longitudinal Investigation of Thromboembolism Etiology (LITE) study. J. Thromb. Haemost. 2009, 7, 1639–1648. [Google Scholar] [CrossRef] [Green Version]
- Freyburger, G.; Macouillard, G.; Labrouche, S.; Sztark, F. Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: Two observational studies in patients undergoing total hip or total knee replacement. Thromb. Res. 2011, 127, 457–465. [Google Scholar] [CrossRef]
- Panova-Noeva, M.; Schulz, A.; Spronk, H.M.; Beicht, A.; Laubert-Reh, D.; van Oerle, R.; Arnold, N.; Prochaska, J.H.; Blettner, M.; Beutel, M.; et al. Clinical Determinants of Thrombin Generation Measured in Presence and Absence of Platelets-Results from the Gutenberg Health Study. Thromb. Haemost. 2018, 118, 873–882. [Google Scholar] [CrossRef]
- Makhoul, S.; Panova-Noeva, M.; Regnault, V.; Ruf, W.; Wenzel, P.; Lagrange, J. Rivaroxaban Effects Illustrate the Underestimated Importance of Activated Platelets in Thrombin Generation Assessed by Calibrated Automated Thrombography. J. Clin. Med. 2019, 8, 1990. [Google Scholar] [CrossRef] [Green Version]
- Ten Cate, V.; Koeck, T.; Panova-Noeva, M.; Rapp, S.; Prochaska, J.H.; Lenz, M.; Schulz, A.; Eggebrecht, L.; Hermanns, M.I.; Heitmeier, S.; et al. A prospective cohort study to identify and evaluate endotypes of venous thromboembolism: Rationale and design of the Genotyping and Molecular Phenotyping in Venous ThromboEmbolism project (GMP-VTE). Thromb. Res. 2019, 181, 84–91. [Google Scholar] [CrossRef]
- Frank, B.; Ariza, L.; Lamparter, H.; Grossmann, V.; Prochaska, J.H.; Ullmann, A.; Kindler, F.; Weisser, G.; Walter, U.; Lackner, K.J.; et al. Rationale and design of three observational, prospective cohort studies including biobanking to evaluate and improve diagnostics, management strategies and risk stratification in venous thromboembolism: The VTEval Project. BMJ Open 2015, 5, e008157. [Google Scholar] [CrossRef] [Green Version]
- Konstantinides, S.V.; Barco, S.; Rosenkranz, S.; Lankeit, M.; Held, M.; Gerhardt, F.; Bruch, L.; Ewert, R.; Faehling, M.; Freise, J.; et al. Late outcomes after acute pulmonary embolism: Rationale and design of FOCUS, a prospective observational multicenter cohort study. J. Thromb. Thrombolysis 2016, 42, 600–609. [Google Scholar] [CrossRef]
- Spronk, H.M.H.; Dielis, A.W.J.H.; Panova-Noeva, M.; van Oerle, R.; Govers-Riemslag, J.W.P.; Hamulyák, K.; Falanga, A.; Cate, H.T. Monitoring thrombin generation: Is addition of corn trypsin inhibitor needed? Thromb. Haemost. 2009, 101, 1156–1162. [Google Scholar]
- Tanaka, K.A.; Katori, N.; Szlam, F.; Sato, N.; Kelly, A.B.; Levy, J.H. Effects of tirofiban on haemostatic activation in vitro. Br. J. Anaesth. 2004, 93, 263–269. [Google Scholar] [CrossRef] [Green Version]
- Zalewski, J.; Stepien, K.; Nowak, K.; Caus, S.; Butenas, S.; Undas, A. Delayed Thrombin Generation Is Associated with Minor Bleedings in Venous Thromboembolism Patients on Rivaroxaban: Usefulness of Calibrated Automated Thrombography. J. Clin. Med. 2020, 9, 2018. [Google Scholar] [CrossRef]
- Perzborn, E.; Heitmeier, S.; Laux, V. Effects of Rivaroxaban on Platelet Activation and Platelet-Coagulation Pathway Interaction: In Vitro and In Vivo Studies. J. Cardiovasc. Pharmacol. Ther. 2015, 20, 554–562. [Google Scholar] [CrossRef] [Green Version]
- Eikelboom, J.W.; Connolly, S.J.; Bosch, J.; Dagenais, G.R.; Hart, R.G.; Shestakovska, O.; Diaz, R.; Alings, M.; Lonn, E.M.; Anand, S.S.; et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N. Engl. J. Med. 2017, 377, 1319–1330. [Google Scholar] [CrossRef]
- Krauss, E.S.; Cronin, M.; Dengler, N.; Simonson, B.G.; Altner, K.; Daly, M.; Segal, A. The Effect of BMI and Gender on Bleeding Events when Rivaroxaban Is Administered for Thromboprophylaxis Following Total Hip and Total Knee Arthroplasty. Semin. Thromb. Hemost. 2019, 45, 180–186. [Google Scholar] [CrossRef]
- D’Alessio, A.; Marchetti, M.; Tartari, C.J.; Russo, L.; Cecchini, S.; Lambregts, K.W.F.M.; di Mauro, D.; Falanga, A. Long Term Low Molecular Weight Heparin Anticoagulant Therapy Modulates Thrombin Generation and D-dimer in Patients with Cancer and Venous Thromboembolism. Cancer Investig. 2017, 35, 490–499. [Google Scholar] [CrossRef]
- Monroe, D.M.; Hoffman, M.; Roberts, H.R. Platelets and thrombin generation. Arterioscler. Thromb. Vasc. Biol. 2002, 22, 1381–1389. [Google Scholar] [CrossRef] [Green Version]
- Königsbrügge, O.; Pabinger, I.; Ay, C. Risk factors for venous thromboembolism in cancer: Novel findings from the Vienna Cancer and Thrombosis Study (CATS). Thromb. Res. 2014, 133, S39–S43. [Google Scholar] [CrossRef]
GMP-VTE | VTE Subsample | p-Value | |
---|---|---|---|
Number (N) | 513 | 180 | - |
Sex (females), % (N) | 44.8 (230) | 40.0 (72) | 0.29 |
Age (years), mean (SD) | 60.3 (15.9) | 60.9 (16.0) | 0.63 |
BMI (kg/m²), median (IQR) | 28.3 (24.7/32.0) | 28.3 (24.5/31.9) | 0.85 |
Platelet count (109/L), median (IQR) | 239.0 (189.7/297.3) | 221.5 (178.0/268.6) | 0.01 |
Leukocytes (103/L), median (IQR) | 8.50 (6.53/11.30) | 8.48 (6.82/11.10) | 0.83 |
Cardiovascular risk factors | |||
Arterial hypertension, % (N) | 49.5 (249) | 55.8 (91) | 0.18 |
Diabetes mellitus, % (N) | 12.4 (62) | 15.9 (26) | 0.29 |
Smoking, % (N) | 16.9 (82) | 17.9 (29) | 0.81 |
Obesity, % (N) | 35.5 (172) | 36.5 (65) | 0.85 |
Comorbidities | |||
Atrial fibrillation, % (N) | 4.2 (21) | 5.5 (9) | 0.52 |
CHF, % (N) | 4.5 (22) | 6.1 (10) | 0.40 |
CAD, % (N) | 7.1 (35) | 8.5 (14) | 0.61 |
Stroke, % (N) | 5.0 (25) | 5.5 (9) | 0.84 |
PAD, % (N) | 3.8 (12) | 6.1 (8) | 0.32 |
Cancer, % (N) | 12.5 (63) | 11.8% (21) | 0.89 |
VTE phenotype | |||
Isolated PE, % (N) | 18.3 (86) | 21.1 (37) | 0.43 |
Isolated DVT, % (N) | 30.4 (156) | 21.1 (38) | 0.02 |
PE+DVT, % (N) | 48.6 (229) | 57.1 (100) | 0.06 |
Therapy | |||
Heparin, % (N) | 57.0 (292) | 67.8 (122) | 0.01 |
FXa inhibitor, % (N) | 26.0 (133) | 23.3 (10) | 0.06 |
Anticoagulants *, % (N) | 75.6 (387) | 80.6 (145) | 0.18 |
Antiplatelets ** | 23.2 (119) | 33.9 (61) | 0.01 |
Contraceptives, % (N) | 4.1 (21) | 6.7 (12) | 0.22 |
Normal Curve | Biphasic Curve | p-Value (Biphasic vs. Normal) | No Curve | p-Value (No Curve vs. Normal) | |
---|---|---|---|---|---|
Number (N) | 110 | 20 | - | 50 | - |
Sex (females), % (N) | 33.6 (37) | 55.0 (11) | 0.081 | 48.0 (24) | 0.11 |
Age (years), mean (SD) | 59.0 (16.7) | 63.5 (13.7) | 0.19 | 64.3 (14.7) | 0.046 |
BMI (kg/m²), mean (SD) | 28.4 (5.2) | 30.7 (7.8) | 0.23 | 29.6 (7.0) | 0.31 |
Platelet count (109/L), median (IQR) | 222.0 (176.2/285.8) | 232.5 (189.7/293.6) | 0.18 | 219.0 (178.0/250.0) | 0.90 |
Leukocytes (103/L), median (IQR) | 8.52 (6.83/11.08) | 9.15 (7.82/10.72) | 0.35 | 7.65 (6.59/11.27) | 0.66 |
Cardiovascular risk factors | |||||
Arterial hypertension, % (N) | 49.5 (49) | 58.8 (10) | 0.60 | 68.1 (32) | 0.049 |
Diabetes mellitus, % (N) | 13.9 (14) | 17.6 (3) | 0.71 | 19.6 (9) | 0.46 |
Smoking, % (N) | 23.0 (23) | 0 (0) | 0.023 | 13.3 (6) | 0.26 |
Obesity, % (N) | 35.5 (39) | 36.8 (7) | 1.00 | 38.8 (19) | 0.72 |
Comorbidities | |||||
Atrial fibrillation, % (N) | 8.0 (8) | 0 (0) | 0.60 | 2.1 (1) | 0.27 |
CHF, % (N) | 6.0 (6) | 5.9 (1) | 1.00 | 6.5 (3) | 1.00 |
CAD, % (N) | 6.9 (7) | 5.9 (1) | 1.00 | 12.8 (6) | 0.35 |
Stroke, % (N) | 3.0 (3) | 0 (0) | 1.00 | 12.8 (6) | 0.029 |
PAD, % (N) | 4.8 (4) | 8.3 (1) | 0.50 | 8.3 (3) | 0.43 |
Cancer, % (N) | 9.3 (10) | 25.0 (5) | 0.059 | 12.0 (6) | 0.58 |
VTE phenotype | |||||
Isolated PE, % (N) | 19.4 (21) | 33.3 (6) | 0.22 | 20.4 (10) | 1.00 |
Isolated DVT, % (N) | 29.1 (32) | 5.0 (1) | 0.024 | 10.0 (5) | 0.0083 |
PE+DVT, % (N) | 50.9 (55) | 61.1 (11) | 0.46 | 69.4 (34) | 0.037 |
Therapy | |||||
Heparin, % (N) | 71.8 (79) | 45.0 (9) | 0.035 | 68.0 (34) | 0.71 |
FXa inhibitor, % (N) | 20.0 (22) | 50.0 (10) | 0.0089 | 20.0 (10) | 1.00 |
Anticoagulants *, % (N) | 80.9 (89) | 75.0 (15) | 0.55 | 82.0 (41) | 1.00 |
Antiplatelets #, % (N) | 59.1 (65) | 45.0 (9) | 0.33 | 58.0 (29) | 1.00 |
Contraceptives, % (N) | 6.4 (7) | 10.0 (2) | 0.63 | 2.0 (1) | 0.44 |
TG in PRP | |||||
Lag time (min) | 11.67 (8.07/18.89) | 12.78 (10.76/18.11) | 0.59 | n.a. | - |
Peak Height (nM) | 63.30 (33.39/102.76) | 43.08 (32.14/66.90) | 0.094 | n.a. | - |
ETP (nM.min) | 1323.27 (926.37/1691.17) | 1464.06 (1194.51/1775.80) | 0.38 | n.a. | - |
Velocity (nM/min) | 5.21 (1.83/11.80) | 1.82 (1.46/3.45) | 0.0025 | n.a. | - |
OR (95% CI) | p-Value | OR * (95% CI) | p-Value | |
---|---|---|---|---|
Sex (females) | 5.14 (1.48; 17.88) | 0.010 | 7.36 (1.76; 30.83) | 0.0063 |
Age (10 years) | 1.21 (0.81; 1.80) | 0.35 | 1.20 (0.73; 1.96) | 0.47 |
Cancer | 6.06 (1.33; 27.70) | 0.020 | 6.14 (1.04; 36.25) | 0.045 |
Isolated DVT | 0.19 (0.02; 1.77) | 0.15 | 0.19 (0.02; 1.94) | 0.16 |
Isolated PE | 1.61 (0.43; 5.95) | 0.48 | 1.25 (0.24; 6.61) | 0.79 |
FXa inhibitor | 7.60 (2.07; 27.93) | 0.0023 | 5.87 (1.33; 25.98) | 0.020 |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Lagrange, J.; Wagner, B.; Nagler, M.; ten Cate, V.; Pallares Robles, A.; Koeck, T.; Rapp, S.; Prochaska, J.H.; Spronk, H.M.; Wenzel, P.; et al. Characterization of Thrombin Generation Curve Shape in Presence of Platelets from Acute Venous Thromboembolism Patients. J. Clin. Med. 2020, 9, 2892. https://doi.org/10.3390/jcm9092892
Lagrange J, Wagner B, Nagler M, ten Cate V, Pallares Robles A, Koeck T, Rapp S, Prochaska JH, Spronk HM, Wenzel P, et al. Characterization of Thrombin Generation Curve Shape in Presence of Platelets from Acute Venous Thromboembolism Patients. Journal of Clinical Medicine. 2020; 9(9):2892. https://doi.org/10.3390/jcm9092892
Chicago/Turabian StyleLagrange, Jeremy, Bianca Wagner, Markus Nagler, Vincent ten Cate, Alejandro Pallares Robles, Thomas Koeck, Steffen Rapp, Jürgen H. Prochaska, Henri M. Spronk, Philip Wenzel, and et al. 2020. "Characterization of Thrombin Generation Curve Shape in Presence of Platelets from Acute Venous Thromboembolism Patients" Journal of Clinical Medicine 9, no. 9: 2892. https://doi.org/10.3390/jcm9092892